Wednesday, October 14, 2026

Private Equity & M&A

4 articles

Private Equity Firms Deploy $23B Across Energy Infrastructure as Transition Accelerates

Private Equity Firms Deploy $23B Across Energy Infrastructure as Transition Accelerates

EQT Infrastructure leads a consortium acquiring AES Corporation while Blackstone and Onex execute billion-dollar deals in energy and industrial assets. The wave of PE acquisitions targets infrastructure modernization and energy transition opportunities despite market volatility forecasts through 2028.

ViaNews Editorial Team (Finance)•
Tikehau Capital Targets €60bn AuM by 2029 as PE Firms Restructure Portfolios

Tikehau Capital Targets €60bn AuM by 2029 as PE Firms Restructure Portfolios

Tikehau Capital set 2026-2029 growth targets of €60bn assets under management and 45-50% core margins, exceeding market expectations by up to 50%. The move leads a wave of PE portfolio repositioning including Onex's Convex acquisition and Wells Fargo's asset management exit to Reverence Capital/GTCR.

ViaNews Editorial Team (Finance)•
Private Equity Deploys Capital in Packaging and Consumer Sectors as Q4 Earnings Show Mixed Corporate Performance

Private Equity Deploys Capital in Packaging and Consumer Sectors as Q4 Earnings Show Mixed Corporate Performance

Five PE firms deployed capital across packaging, consumer goods, and specialty sectors in February 2026, while Q4 2025 earnings revealed divergent performance. Star Equity posted $48M revenue (+30% YoY) with $3.1M pro forma adjusted EBITDA following its Hudson Global merger, while tech stocks swung violently on guidance shifts—Nvidia up 5.79%, Monday.com down 20%.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com